Recent Pfizer Press Releases

  • 12/14/18 8:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. “While the full extent of Prevenar 13 protection of adults is still being realized, we anticipate our 20vPnCmore...
  • 12/2/18 3:45 pm EST
    • 26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma
    • The U.S. Food and Drug Administration (FDA) accepted for review, a Biologics License Application (BLA) for PF-05280586 in September 2018
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy study of PF-05280586 versus Rituxan®/MabThera® (rituximab-EU)i, met its primary endpoint of overall response rate (ORR) at Week 26 of the 52-week study.1 “It is encouraging to see new data supporting a potential rituximab Biosimilar. If approved this maymore...
  • 11/30/18 10:00 am EST

    All Intellectual Property Matters for Pfizer’s Proposed Adalimumab Biosimilar Resolved

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer’s proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer’s proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilarmore...
  • 11/27/18 3:01 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA®. This grant extends the period of U.S. market exclusivity for LYRICA by an additional six months, to June 30, 2019. LYRICA is currently approved in the U.S. for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults. LYRICA is also approvedmore...
  • 11/21/18 1:40 pm EST

    DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML

    In a randomized Phase 2 trial, DAURISMO plus low-dose chemotherapy significantly improved median overall survival in patients who were not able to receive intensive chemotherapy due to age or comorbidities – a difficult-to-treat patient population

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved DAURISMO™ (glasdegib), a once-daily oral medicine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is taken in combination with low-dose cytarabine (LDAC), a type of chemotherapy.more...
  • 11/21/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on Wednesday, November 28, 2018 at 8:45 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registeringmore...
  • 11/2/18 4:42 pm EDT

    LORBRENA Addresses Unmet Needs for Certain Patients Treated With Prior ALK Therapy

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease hasmore...
  • 10/30/18 6:45 am EDT
    • Third-Quarter 2018 Revenues of $13.3 Billion, Reflecting 2% Operational Growth
    • Third-Quarter 2018 Reported Diluted EPS(1) of $0.69, Adjusted Diluted EPS(2) of $0.78
    • Narrowed Certain 2018 Financial Guidance Ranges; Midpoint of Updated Adjusted Diluted EPS(2) Guidance Range of $2.98 to $3.02 is Unchanged from July 2018
    • Repurchased $1.1 Billion of Common Stock in Third-Quarter 2018 and $9.0 Billion to Date in 2018; Now Expect to Repurchase Approximately $12 Billion of Shares in 2018
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2018 and narrowed certain 2018 financial guidance ranges. Results for the third quarter and first nine months of 2018 and 2017(3) are summarized below. OVERALL RESULTS ($ in millions, exceptmore...
  • 10/29/18 2:15 am EDT

    Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into a non-exclusive clinical development agreement with Novartis (NYSE: NVS) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH). The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304,more...
  • 10/23/18 6:40 pm EDT

    Over Half of Patients Treated with Tanezumab Reported a 50 Percent or Greater Reduction in Osteoarthritis Pain of the Knee or Hip

    Pfizer and Lilly Present Late-Breaking Data at 2018 ACR/ARHP Annual Meeting

    NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis (OA) pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating that among patients with moderatemore...